| Literature DB >> 24235887 |
Harmanpreet Singh1, Mandeep Kaur, Hitesh Verma.
Abstract
Patients, especially children, are the most difficult to treat in all groups of population mainly because they can not swallow the solid dosage form. Due to this reason they are often prescribed liquid dosage forms. But these formulations have their own disadvantages (lack of dose accuracy during administration, spitting by children, spillage, lack of stability, difficulty in transportation, etc.). Oral strip technology is one such technology to surpass these disadvantages. Desloratadine, a descarboethoxy derivative of loratadine, is a second generation antihistaminic drug approved for usage in allergic rhinitis among paediatric population and is available in markets as suspension. An attempt has been made to design and optimize the oral strip containing desloratadine as an active ingredient. Oral strip was optimized with the help of optimal experimental design using polymer concentration, plasticizer type, and plasticizer concentration as independent variables. Prepared oral strips were evaluated for physicochemical parameter, mechanical strength parameters, disintegration time, dissolution, surface pH, and moisture sorption tendency. Optimized formulation was further evaluated by scanning electron microscopy, moisture content, and histological alteration in oral mucosa. Accelerated stability studies were also carried out for optimized formulations. Results were analysed with the help of various statistical tools at P < 0.05 and P < 0.01.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24235887 PMCID: PMC3818976 DOI: 10.1155/2013/395681
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1Preparation of OS of DSL.
Optimal design of OS of DSL (Design-Expert version 8 software).
| Formulation code | Plasticizer | Plasticizer (%) | MDX : HPMC |
|---|---|---|---|
| F1 | Glycerine | 15.0 | 3 : 7 |
| F2 | Glycerine | 20.0 | 5 : 5 |
| F3 | Glycerine | 20.0 | 3 : 7 |
| F4 | Glycerine | 20.0 | 5 : 5 |
| F5 | Glycerine | 20.0 | 1 : 9 |
| F6 | Glycerine | 25.0 | 3 : 7 |
| F7 | Glycerine | 25.0 | 1 : 9 |
| F8 | Glycerine | 15.0 | 5 : 5 |
| F9 | Glycerine | 25.0 | 3 : 7 |
| F10 | Glycerine | 15.0 | 1 : 9 |
| F11 | Glycerine | 20.0 | 1 : 9 |
| F12 | Glycerine | 25.0 | 5 : 5 |
| F13 | Glycerine | 15.0 | 3 : 7 |
| F14 | PEG 400 | 25.0 | 1 : 9 |
| F15 | PEG 400 | 25.0 | 3 : 7 |
| F16 | PEG 400 | 15.0 | 3 : 7 |
| F17 | PEG 400 | 20.0 | 5 : 5 |
| F18 | PEG 400 | 20.0 | 3 : 7 |
| F19 | PEG 400 | 25.0 | 5 : 5 |
| F20 | PEG 400 | 15.0 | 1 : 9 |
| F21 | PEG 400 | 25.0 | 5 : 5 |
| F22 | PEG 400 | 20.0 | 1 : 9 |
| F23 | PEG 400 | 15.0 | 1 : 9 |
| F24 | PEG 400 | 15.0 | 5 : 5 |
Saturated solubility studies of DSL (alone and in presence of poloxamers).
| Composition | Solubility in PBS (mg/mL) | ||||
|---|---|---|---|---|---|
| N1 | N2 | N3 | Mean | SD | |
| DSL | 3.21 | 3.43 | 3.09 | 3.24 | 0.17 |
| DSL + P188 (0.5% w/v) | 3.92 | 4.04 | 4.21 | 4.06 | 0.15 |
| DSL + P188 (2.0% w/v) | 4.11 | 4.26 | 4.3 | 4.22 | 0.10 |
| DSL + P188 (4.0% w/v) | 4.24 | 4.37 | 4.33 | 4.31 | 0.07 |
| DSL + P407 (0.5% w/v) | 3.74 | 3.96 | 3.82 | 3.84 | 0.11 |
| DSL + P407 (2.0% w/v) | 3.89 | 3.95 | 3.91 | 3.92 | 0.03 |
| DSL + P407 (4.0% w/v) | 4.2 | 4.27 | 4.35 | 4.27 | 0.08 |
N1, N2, and N3: replicate measurements; SD: Standard Deviation.
Figure 2Saturated solubility study of DSL in presence of poloxamer P188 and P407.
Physicochemical characterization of OS of DSL (n = 10).
| Formulation code | Content (%) | Weight variation (%) | Thickness (mm) |
|---|---|---|---|
| F1 | 97.23 | −2.83 | 0.21 ± 0.02 |
| F3 | 98.88 | 1.16 | 0.28 ± 0.03 |
| F4 | 99.2 | −2.83 | 0.25 ± 0.07 |
| F5 | 99.92 | −0.17 | 0.26 ± 0.02 |
| F6 | 100.13 | 3.16 | 0.23 ± 0.04 |
| F7 | 101.34 | −2.16 | 0.202 ± 0.00 |
| F8 | 103.02 | −0.17 | 0.24 ± 0.00 |
| F10 | 99.4 | −0.17 | 0.24 ± 0.03 |
| F12 | 97.11 | −4.83 | 0.35 ± 0.03 |
| F14 | 97.43 | 1.83 | 0.31 ± 0.03 |
| F15 | 99.92 | 1.16 | 0.35 ± 0.04 |
| F16 | 100.45 | 3.83 | 0.29 ± 0.03 |
| F17 | 104.32 | 3.83 | 0.21 ± 0.02 |
| F18 | 102.09 | −4.16 | 0.24 ± 0.05 |
| F21 | 99.89 | −0.17 | 0.34 ± 0.05 |
| F22 | 103.78 | −0.83 | 0.41 ± 0.03 |
| F23 | 101.22 | −2.83 | 0.39 ± 0.01 |
| F24 | 100.32 | 1.83 | 0.37 ± 0.04 |
Figure 3Weight variation analysis of OS of DSL (n = 10).
Figure 4Thickness analysis of OS of DSL (n = 10).
Mechanical properties of OS of DSL.
| Formulation code | Tensile strength (MPa) | Elongation (%) |
|---|---|---|
| F1 | 13.1 | 22.9 |
| F3 | 12.6 | 27.8 |
| F4 | 9.0 | 45.2 |
| F5 | 11.5 | 65.4 |
| F6 | 2.7 | 69.9 |
| F7 | 11.4 | 78.9 |
| F8 | 30.2 | 42.5 |
| F10 | 12.1 | 37.1 |
| F12 | 2.5 | 88.2 |
| F14 | 11.8 | 63.8 |
| F15 | 10.2 | 52.3 |
| F16 | 25.4 | 34.1 |
| F17 | 8.8 | 72.3 |
| F18 | 12.4 | 38.3 |
| F21 | 3.1 | 78.8 |
| F22 | 14.8 | 63.5 |
| F23 | 24.3 | 39.7 |
| F24 | 11.2 | 75.4 |
Figure 5Moisture uptake analysis: (a) formulations containing glycerine and (b) formulations containing PEG 400.
In vitro disintegration test, surface pH test, and in vitro dissolution test of OS loaded with DSL.
| Formulation code | Disintegration time (s) | Surface pH | Dissolution (%) within 4 minutes |
|---|---|---|---|
| F1 | 5 | 6.7 | 24.45 |
| F3 | 9 | 6.7 | 31.24 |
| F4 | 12 | 6.7 | 45.75 |
| F5 | 12 | 6.7 | 23.26 |
| F6 | 15 | 6.8 | 57.34 |
| F7 | 20 | 6.6 | 47.32 |
| F8 | 16 | 6.8 | 35.37 |
| F10 | 24 | 6.5 | 21.2 |
| F12 | 9 | 6.7 | 37.66 |
| F14 | 21 | 6.8 | 37.82 |
| F15 | 13 | 6.8 | 38.34 |
| F16 | 17 | 6.8 | 32.11 |
| F17 | 14 | 6.7 | 67.83 |
| F18 | 15 | 6.8 | 41.34 |
| F21 | 11 | 6.8 | 43.91 |
| F22 | 17 | 6.6 | 28.6 |
| F23 | 21 | 6.7 | 23.78 |
| F24 | 17 | 6.7 | 39.21 |
Figure 6In vitro dissolution test of OS loaded with DSL: (a) formulations containing glycerine and (b) formulations containing PEG 400.
Figure 7SEM of optimised formulation F12 (a) without poloxamer P188 and (b) with poloxamer P188.